UK and US Stem Cell Banks team up to share expertise

Published: 16-Mar-2011
Research & Development

Plan to drive forward stem cell research

The UK Stem Cell Bank, based at the Health Protection Agency’s National Institute for Biological Standards and Control (NIBSC) in Hertfordshire, and the Human Stem Cell Bank and Registry at the University of Massachusetts (UMASS) Medical School in the US, plan to share stem cell expertise and technology.

The UK and UMASS Stem Cell Banks have signed a Memorandum of Understanding (MOU) that will outline plans for cooperation in a variety of stem cell areas including the delivery of stem cell lines for clinical use.

The agreement outlines plans for the two stem cell banks to work together to ensure that best practice and high standards in stem cell banking are employed at both sites. They will also develop international training events for scientists involved in stem cell research.

Stem cells are the body's 'master cells', with the potential to become many different types of tissue. It is hoped that stem cell treatments may be used in future to help people with Parkinson's disease, diabetes or multiple sclerosis by repairing and replacing diseased and damaged body tissue.

The UK Stem Cell Bank, funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council, is a repository for human cell lines, derived from stem cells. It also holds new and existing adult, foetal and embryonic stem cell lines. Stem cell lines are provided only to accredited researchers to ensure the safe and ethical development of any potential stem cell therapy.

Dr Stephen Inglis, director of HPA's NIBSC said: ‘International co-operation is vital in this fast moving field and we expect that the partnership will accelerate the development of important new therapies, as well as keeping the UK at the forefront of stem cell research.’

Joseph Laning, senior director of the Human Stem Cell Bank and Registry at UMASS Medical School, added: ‘Both banks share common goals and needs. Working in concert allows us to develop strategies that will shape stem cell production, characterisation, banking and distribution in a dynamic field. Each bank brings its own unique attributes to bear in a way that will enhance our influence in the field.’

See more

You may also like

Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Read more
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing

Trending Articles

  1. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
  2. Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
  3. L.B. Bohle hosts successful continuous manufacturing workshop in Brazil Focus on continuous wet granulation and drying for research, development and small-scale production
  4. AstraZeneca's tozorakimab meets primary endpoint in both Phase III COPD trials AstraZeneca has reported positive results from the OBERON and TITANIA Phase III trials, with tozorakimab significantly reducing moderate-to-severe COPD exacerbations compared to placebo
  5. From powder to granules: a deep dive into wet granulation methods - WEBINAR NOW ON DEMAND Join ACG in partnership with Manufacturing Chemist for an expert-led session to explore how different wet granulation methods impact consistency, yield, and quality — and what really matters when it comes to selecting and optimising your process

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing

Degasser for volatile and aggressive solvents

Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development

Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer

The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies
Research & Development

University of Exeter leads £4.5m Wellcome-funded initiative to develop bioimaging tools for fungal pathogens

An international collaboration spanning the universities of Exeter, Edinburgh and Cape Town has secured £4.5m to develop specialist bioimaging tools for WHO-priority fungal pathogens
Subscribe now